12:00 AM
Dec 23, 2013
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Evolocumab: Phase II data

The open-label, international Phase II OSLER extension trial in 1,104 patients with high cholesterol showed that once-monthly 420 mg subcutaneous evolocumab plus standard of care (SOC) led to a 52.3% mean reduction in LDL-C from baseline to week 52 in patients who were randomized to the control arm in a prior Phase II trial of evolocumab. In patients who received evolocumab in a prior Phase II trial, continued treatment with evolocumab...

Read the full 334 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$30 USD
More Info >